WO2002045858A2 - Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient - Google Patents
Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient Download PDFInfo
- Publication number
- WO2002045858A2 WO2002045858A2 PCT/FR2001/003889 FR0103889W WO0245858A2 WO 2002045858 A2 WO2002045858 A2 WO 2002045858A2 FR 0103889 W FR0103889 W FR 0103889W WO 0245858 A2 WO0245858 A2 WO 0245858A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compartment
- reaction
- barrier
- reagent
- state
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5025—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00178—Special arrangements of analysers
- G01N2035/00237—Handling microquantities of analyte, e.g. microvalves, capillary networks
- G01N2035/00247—Microvalves
- G01N2035/00267—Meltable plugs
Definitions
- Temporary separation barrier, container comprising it and method for setting up a test in this container
- the invention relates to a barrier for the temporary separation of a reaction vessel, to said reaction vessel as well as to a method for carrying out a test in the reaction vessel.
- the reaction takes place in the first compartment and the second compartment is arranged to allow the revelation of the possible reaction, in particular by specific bonding of the reaction product with a substance placed in the second compartment.
- This type of barrier has the function on the one hand of isolating the second compartment from the reaction medium and on the other hand of allowing, under the effect of external forces and at the desired time, the selective passage from the first to the second compartment certain elements of the reaction medium among the analyte, the reagent and the product of their reaction.
- Such containers are for example intended to allow carrying out biological tests based on the reaction between an analyte present in a biological fluid and a reagent capable of forming a complex with said analyte.
- This type of test typically applies to research, in blood or in a blood component, of antigens present on the surface of red blood cells using known anti-erythrocyte antibodies (erythrocyte typing) or research anti-erythrocyte antibodies using red blood cells on which specific antigens are present and / or attached.
- Separation barriers of a physical type are already known, for example formed from a membrane or a sieve of plastic material, which are arranged between a first and a second compartment of a container.
- This type of barrier has the disadvantage of not being modifiable after the introduction of the reaction medium into the first compartment.
- this type of embodiment requires providing a particular barrier shape depending on the shape and / or the size of the container.
- Separation barriers are also known, for example formed from agars, which are temporary.
- this type of barrier has the drawbacks of poor reliability and of a phase change linked to a change in temperature which may not be desirable for the reaction which has to take place in the container.
- the invention therefore aims to remedy all of these drawbacks by proposing in particular a separation barrier which can pass, in a simple and reliable manner, from a state impermeable to the reaction medium to a state where it is capable of allowing passage from the first to the second compartment certain elements among the analyte, the reagent or the product of their reaction, and this at the chosen time and without any particular constraint for the reaction which must take place in the container.
- the invention provides a barrier for the temporary separation of a reaction vessel into at least a first compartment into which a reaction medium comprising an analyte and optionally a reagent is introduced and a second compartment intended receiving at least one of the elements from the reagent, the analyte and the reaction product, said barrier being formed of a material capable of passing, by the action of a specific chemical substance, from a first state in wherein said material is substantially impermeable to the reaction medium in a second state in which said material is capable of allowing at least one of said elements to pass through the reagent, the analyte and the product of the reaction.
- the invention provides a reaction container comprising a barrier described above, said container being in the form of a micro-well of a micro-titration plate, said micro-well having a shape in U or V
- the invention provides a method for carrying out a test in a reaction vessel described above, said method comprising the steps providing for:
- FIG. 1 represents, in section and schematically, a container comprising a temporary separation barrier according to the invention.
- a reaction vessel for example made of rigid plastic material, which is in the form of a micro-well of a micro-titration plate, said micro-well having a shape U.
- the container is part of a device comprising eight micro-wells 1 of a micro-titration plate, and has a unit capacity of between 300 and 350 ⁇ l, a diameter of approximately 6 mm and a height about 8 mm.
- the container 1 can be hermetically sealed with a peelable sheet, for example of special aluminum, so as to avoid possible pollution of its content.
- the container 1 is divided by a temporary separation barrier 2 into a first compartment 3 into which a reaction medium comprising an analyte and optionally a reagent is introduced and a second compartment 4 intended to receive at least one of the elements from the reagent, the analyte and the product of their reaction.
- the container 1 can be divided into more than two compartments 3, 4.
- the container 1 can be divided into three compartments by two separate barriers 2, the first receiving the reaction medium, the second receiving the reaction product and containing a second reagent and the third receiving the reaction product to occur in the second compartment.
- the container 1 has a U-shape, the opening part forming the first compartment 3 and the base part forming the second compartment 4.
- the container 1 has in particular the function of allowing a possible reaction between an analyte and a reagent.
- the barrier 2 is formed from a material, in particular a biological material which, in a first state, is substantially impermeable to the reaction medium so as to isolate the first compartment 3 from the second compartment 4.
- the biological material in its first state by acting as a physical barrier vis-à-vis the reaction medium, allows the reaction to be carried out in the first compartment 3 without risk of diffusion of the reaction medium in the second compartment 4.
- the barrier 2 has the function of isolating the second compartment 4, for example to subject the reaction medium to a particular treatment.
- the container 1 also has the function of allowing the passage of certain elements of the reaction medium into the second compartment 4 in order, for example, to allow them to be brought into contact with a substance 5 such as a reagent or a substance allowing the character to be revealed in situ. positive or negative of the test.
- the biological material forming barrier 2 is capable of passing, by the action of a specific chemical substance, from the first state to a second state in which said material is capable of allowing at least one of the elements to pass through.
- reagent, the analyte and the product of their reaction In a first particular example, the biological material in its second state allows the revelation of the test in the first or in the second compartment 3, 4 depending on the elements which it lets through.
- a substance 5 capable of specifically binding to the reaction product can be placed in the second compartment 4, for example by being fixed on substantially the entire curved internal wall 6 of the base part 7 of the container 1.
- This embodiment is particularly desirable when the biological material does not allow only the reaction product, but the reaction product and the reagent or the analyte, to allow visualization of the presence of the reaction product by specific fixation. of it on substance 5.
- the second compartment 4 can be filled with the biological material forming the barrier 2 so that it also serves to protect the substance 5 capable of specifically binding to the reaction product.
- the container 1 allows the chain reaction to be carried out by providing that a second reagent to react with the product of the reaction is placed in the second compartment 4.
- a second reagent to react with the product of the reaction is placed in the second compartment 4.
- provision may be made not to introduce a reagent in the first compartment 3 but for the latter to be disposed in the barrier 2 and / or in the second compartment 4.
- the biological fluid is introduced into the first compartment 3 and, after a possible treatment, at least the analyte passes through the barrier 2 in its second state in order to be brought into contact with the reagent.
- This embodiment makes it possible to bring the reagent and the analyte into contact at a given time and optionally with a determined kinetics in the case where the reagent is placed in the barrier 3.
- the second compartment does not comprise any reagent or specific substance and the biological material in its second state only serves as a filter between the elements of the reaction medium.
- the barrier also comprises the specific chemical substance capable of passing the material from its first to its second state.
- radiation can initiate, at the desired moment, the action of the chemical substance on the material so as to cause it to pass from its first to its second state.
- container 1 for example in V, containers 1 whose surface 6 on which the substance 5 is fixed is of convex shape, or even that the two compartments 3, 4 are not arranged vertically but for example transversely.
- a container 1 intended to allow the realization and the development of a reaction between an analyte present in a biological fluid, in particular blood or a blood component such as a plasma or a serum, and a reagent.
- the biological fluid and the reagent include protein elements and / or figurative elements.
- the purpose of the analysis is to reveal the presence of a particular figurative element in the biological fluid.
- the reagent which is able to bind specifically with the desired figured element to form a complex with it is then in protein form.
- a particular example of such an analysis is when the analyte is a red cell carrying a blood group antigen and the reagent comprises a known antibody which is capable of binding to this antigen.
- This analysis makes it possible in particular to determine the group or the phenotype of the red blood cell.
- the terms “figured element” and “complex” refer respectively to the cellular elements of the biological fluid or of the reagent and to the complexes formed by specific bonds with these elements.
- the purpose of the analysis is to reveal the presence of a particular protein element in the biological fluid.
- the reagent which is able to bind specifically with the desired protein element to form a complex with it is then in figurative form.
- a particular example of such an analysis is when the reagent comprises red cells carrying a known blood group antigen and the analyte is an antibody to a serum which is capable of binding to this antigen.
- This analysis makes it possible in particular to determine the presence and the nature of an antibody of the immune type prior to a transfusion.
- an embodiment of the substance 5 capable of specifically binding this with the complexes possibly formed is for example formed of human anti-immunoglobulin (AGH) antibodies of monoclonal and / or polyclonal origin, optionally supplemented with antibodies directed against determinants of serum proteins of the complement type.
- AGH human anti-immunoglobulin
- the biological material is, in its first state, in the form of a solid gel or of dense texture and, in its second state, in the form of a liquid.
- Biological material using a mixture of sodium alginates, bovine albumin, sodium pyrophosphate and calcium chloride is used.
- the biological material is introduced into the container 1 in liquid form and then the gelation is obtained after an incubation time greater than one hour.
- This gelation time allows the fluid to distribute well above the substance 5 with a good surface condition.
- the gel thus obtained allows the distribution of the reaction medium in the first compartment 3 at speeds of the order of 400 ⁇ l / sec without causing any leakage of reaction medium in the second compartment 4.
- the transition between the first state and the second is achieved by a phase change of the biological material which is caused by a specific chemical substance.
- the specific chemical substance capable of depolymerizing the gel described above is an agent complexing divalent ions, for example EDTA or sodium citrate, which causes its liquefaction.
- the sodium alginates used have the property of forming, in the presence of divalent ions, a dense network (first state of the biological material). This network is however reversible because in the presence of agents complexing divalent ions, there is a rearrangement and / or dissociation of the alginate chains causing a liquefaction of the gel (second state of the biological material).
- the kinetics of this liquefaction is linked to the concentration of sequestering agent, to the temperature and to possible agitation.
- the density of the biological material in the second state may be different from the elements having to pass through the barrier 2.
- the density of the biological material can be between that of the reaction product and that of the reagent so that on the one hand the reagent remains in the first compartment 3 and on the other hand at least the product of the reaction passes into the second compartment 4.
- the density of the biological material in its second state may have a gradient in a longitudinal direction.
- Separation can also be obtained by a difference in physico-chemical affinity, for example by a difference in miscibility, between the biological material on the one hand and the product of the reaction or the reagent on the other hand.
- the biological material in its second state has the function, by its density and / or its composition, of allowing, under the effect of external forces, the passage of at least the product of the reaction in order to allow the test to be carried out in the second compartment 4.
- this function may also be desirable, in order to avoid that the transfer of the reaction product does not entail, in particular by drainage effect, the reagent in the second compartment 4.
- barrier 2 may also comprise an active product in the production and / or the development of the reaction between the reagent and the analyte, for example in the form of an enzymatic solution which will be released into the reaction medium when the biological material will pass into its second state.
- an active product in the production and / or the development of the reaction between the reagent and the analyte, for example in the form of an enzymatic solution which will be released into the reaction medium when the biological material will pass into its second state.
- a 1.2% (weight / volume) solution of partially hydrolyzed sodium alginates (manuronic acid / guluronic acid ratio between 0.8 and 1) and of 15 mM tetra-sodium pyrophosphate is prepared by dissolving an extract dry commercial alginates and sodium pyrophosphate in LISS buffer (Low lonic Strengh Solution). To ensure perfect dissolution of the product, vigorous stirring is carried out. Any bubbles formed are removed using softer stirring. This solution is stored at 4 ° C. Before use, the solution will be brought to room temperature.
- a 150 g / l albumin solution is prepared by diluting with a LISS half-buffer a commercial albumin preparation at 300 g / l. This solution is stored at 4 ° C. Before use, the solution will be brought to room temperature.
- a solution of LISS buffer of calcium chloride at a concentration of 10 mM is used. This solution is stored at 4 ° C. Before use, the solution will be brought to room temperature.
- a LISS buffer solution of ethylene diamine tetra-acetic tetrasodium salt is prepared at a concentration of 100 mM. The pH of this solution is adjusted to 7. This solution is stored at 4 ° C. Before use, the solution will be brought to room temperature.
- a volume-to-volume mixture of the alginate and pyrophosphate solution and the albumin solution is carried out. After gentle stirring for a few minutes, to one volume of this solution is added one volume of the calcium chloride solution. This mixture is quickly homogenized and then distributed in micro-wells 1 at the rate of 100 ⁇ l per well before the start of gelation so as to completely cover the layer of AGH 5 (the time of preparation and handling of such a product must not exceed thirty minutes). A minimum one hour incubation provides a translucent and resistant gel.
- the gelling step takes place slowly enough to allow easy industrialization of the device and the absence of washing allows its implementation easily and possibly fully automated.
- micro-well 1 is then ready for use and must be stored at 4 ° C.
- the depolymerization of the gel is obtained by dispensing approximately 50 ⁇ l per well 1 of a solution containing 100 mM of EDTA (other products complexing calcium ions can also be used). Complete liquefaction of the gel is obtained after an incubation of approximately 15 minutes at a temperature of 20 ° C.
- the preparation and distribution of the barrier 2 of biological material are thus carried out in one step and, the fact of mixing in a precise order and at given concentrations the different constituents of this barrier 2 makes it possible to obtain a homogeneous gel throughout its mass and whose depolymerization is perfectly controllable and takes place simply in the axis of the microwells 1.
- the passage of the material from its first state to its second state is carried out by introduction of the specific chemical substance into the first compartment 3.
- the passage of the material from its first state to its second state is carried out by activation of the specific chemical substance, for example by means of radiation.
- This embodiment is understood as well in the case where the specific chemical substance has been introduced into the first compartment as in the case where said substance is present in the barrier.
- the method comprises a prior step of placing the biological barrier 2 inside the container 1.
- the reagent and the specific chemical substance can be introduced simultaneously so that the reactions on the one hand between the analyte and the reagent and on the other hand between the biological material and the chemical substance take place simultaneously.
- the reaction mixture present in the first compartment 3 can be subjected to conditions favoring the reaction between the analyte and the reagent, for example an incubation so as to increase the speed of the reactions before happen.
- the external force comprises a centrifugal force whose intensity, direction and duration are adjusted to allow the transfer of the desired elements.
- the external force comprises, possibly in addition to a centrifugal force, a magnetic force.
- the magnetic force is created, for example by a permanent magnet or by an electromagnet, in a substantially longitudinal direction relative to the container 1.
- the elements having to pass through the barrier must be or must be made sufficiently paramagnetic to migrate from the first compartment 3 to the second compartment 4 under the effect of the magnetic force.
- red cells of which the group and the phenotype are known it is desired, using red cells of which the group and the phenotype are known, to detect and determine the nature of an antibody of the immune type, that is to say developed following immunization during a blood transfusion or pregnancy.
- the presence of such antibodies can seriously compromise any new transfusion of incompatible blood in the system considered and in the event of pregnancy have serious consequences for the survival of the fetus.
- This regularly performed analysis is called Irregular Agglutinin Research (RAI).
- the reagent comprises red cells carrying a known blood group antigen and the analyte is an antibody capable of binding to this antigen.
- this solution may include the gel depolymerizing agent.
- the antibodies specifically linked to the red cell surface antigens will interact with the antibodies adsorbed on the internal wall 6 of the container 1.
- red blood cell carpet in the case of a positive reaction, an image of red blood cell carpet will be formed, the uniformity and dimensions of which will depend on the quantity of antibodies sought. If the reaction is negative, a central point of red blood cells will appear in the bottom 7 of the container 1.
- the analyte is a red cell carrying a blood group antigen and the reagent can comprise a known antibody which is capable of binding to this antigen.
- the barrier 2 makes it possible, during an analysis, to carry out a temporary isolation of the reaction medium in the first compartment 3 in order to allow the reaction to be carried out or a treatment of the reaction medium and then, at the desired moment, to selectively pass a part of the elements present in the reaction medium to a second compartment 4 in order to allow the revelation of the positive or negative nature of the analysis or to allow the desired elements to be brought into contact with a reagent placed in the barrier 2 and / or in the second compartment 4.
- barrier 2 allows
- the barrier 2 can be used in containers 1 of any shape and in which the current solutions are not satisfactory.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/433,886 US20040067168A1 (en) | 2000-12-08 | 2001-12-07 | Temporary separation barrier, container comprising same and method for carrying out a test in said container |
AU2002217218A AU2002217218A1 (en) | 2000-12-08 | 2001-12-07 | Temporary separation barrier, container comprising same and method for carrying out a test in said container |
EP01999433A EP1342089A2 (fr) | 2000-12-08 | 2001-12-07 | Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/16025 | 2000-12-08 | ||
FR0016025A FR2817961B1 (fr) | 2000-12-08 | 2000-12-08 | Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002045858A2 true WO2002045858A2 (fr) | 2002-06-13 |
WO2002045858A3 WO2002045858A3 (fr) | 2002-07-11 |
Family
ID=8857445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003889 WO2002045858A2 (fr) | 2000-12-08 | 2001-12-07 | Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040067168A1 (fr) |
EP (1) | EP1342089A2 (fr) |
AU (1) | AU2002217218A1 (fr) |
FR (1) | FR2817961B1 (fr) |
WO (1) | WO2002045858A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006124318A3 (fr) * | 2005-05-13 | 2007-05-10 | Honeywell Int Inc | Plate-forme a base de cellules destinee a un criblage a debit eleve |
DE102006024927B4 (de) * | 2006-05-25 | 2008-12-11 | DRK-Blutspendedienst Baden-Württemberg-Hessen gemeinnützige GmbH | Verfahren zum Nachweis von Antikörpern und/oder Antigenen sowie zur Blutgruppenbestimmung in einer Testsubstanz |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005309140A (ja) * | 2004-04-22 | 2005-11-04 | Toshiba Corp | フォトマスク製造方法、フォトマスク欠陥修正箇所判定方法、及びフォトマスク欠陥修正箇所判定装置 |
US20060093528A1 (en) | 2004-10-18 | 2006-05-04 | Applera Corporation | Device including a dissolvable structure for flow control |
US20070059782A1 (en) * | 2005-09-13 | 2007-03-15 | Graham Henry A | Magnetic particle tagged blood bank reagents and techniques |
US9488665B2 (en) * | 2005-09-13 | 2016-11-08 | Chrome Red Technologies, Llc | Magnetic particle tagged reagents and techniques |
GB2435510A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | Enzyme detection product and methods |
GB2435512A (en) * | 2006-02-23 | 2007-08-29 | Mologic Ltd | A binding assay and assay device |
GB2435511A (en) * | 2006-02-23 | 2007-08-29 | Mologic Ltd | Protease detection |
GB2437311A (en) * | 2006-04-07 | 2007-10-24 | Mologic Ltd | A protease detection product |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522923A (en) * | 1983-10-03 | 1985-06-11 | Genetic Diagnostics Corporation | Self-contained assay method and kit |
EP0634216A2 (fr) * | 1993-07-16 | 1995-01-18 | Ortho Diagnostic Systems Inc. | Récipient pour réaction d'agglutination et séparation |
US5411876A (en) * | 1990-02-16 | 1995-05-02 | Hoffmann-La Roche Inc. | Use of grease or wax in the polymerase chain reaction |
US5665582A (en) * | 1990-10-29 | 1997-09-09 | Dekalb Genetics Corp. | Isolation of biological materials |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923680A (en) * | 1987-09-18 | 1990-05-08 | Eastman Kodak Company | Test device containing an immunoassay filter with a flow-delaying polymer |
US5135872A (en) * | 1989-04-28 | 1992-08-04 | Sangstat Medical Corporation | Matrix controlled method of delayed fluid delivery for assays |
US5576197A (en) * | 1995-04-07 | 1996-11-19 | Molecular Bio-Products | Polymerase chain reaction container and methods of using the same |
US5756049A (en) * | 1996-10-25 | 1998-05-26 | Hach Company | Water testing capsule using water soluble film membranes |
-
2000
- 2000-12-08 FR FR0016025A patent/FR2817961B1/fr not_active Expired - Fee Related
-
2001
- 2001-12-07 AU AU2002217218A patent/AU2002217218A1/en not_active Abandoned
- 2001-12-07 US US10/433,886 patent/US20040067168A1/en not_active Abandoned
- 2001-12-07 WO PCT/FR2001/003889 patent/WO2002045858A2/fr not_active Application Discontinuation
- 2001-12-07 EP EP01999433A patent/EP1342089A2/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522923A (en) * | 1983-10-03 | 1985-06-11 | Genetic Diagnostics Corporation | Self-contained assay method and kit |
US5411876A (en) * | 1990-02-16 | 1995-05-02 | Hoffmann-La Roche Inc. | Use of grease or wax in the polymerase chain reaction |
US5665582A (en) * | 1990-10-29 | 1997-09-09 | Dekalb Genetics Corp. | Isolation of biological materials |
EP0634216A2 (fr) * | 1993-07-16 | 1995-01-18 | Ortho Diagnostic Systems Inc. | Récipient pour réaction d'agglutination et séparation |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006124318A3 (fr) * | 2005-05-13 | 2007-05-10 | Honeywell Int Inc | Plate-forme a base de cellules destinee a un criblage a debit eleve |
US7629115B2 (en) | 2005-05-13 | 2009-12-08 | Honeywell International Inc. | Cell-based platform for high throughput screening |
DE102006024927B4 (de) * | 2006-05-25 | 2008-12-11 | DRK-Blutspendedienst Baden-Württemberg-Hessen gemeinnützige GmbH | Verfahren zum Nachweis von Antikörpern und/oder Antigenen sowie zur Blutgruppenbestimmung in einer Testsubstanz |
Also Published As
Publication number | Publication date |
---|---|
EP1342089A2 (fr) | 2003-09-10 |
FR2817961B1 (fr) | 2003-08-01 |
US20040067168A1 (en) | 2004-04-08 |
WO2002045858A3 (fr) | 2002-07-11 |
AU2002217218A1 (en) | 2002-06-18 |
FR2817961A1 (fr) | 2002-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1957978B1 (fr) | Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin | |
EP0015841B1 (fr) | Nouveaux tests par agglutination pour la détection des virus de la grippe, réactifs pour la réalisation de ces tests, procédé de préparation de ces réactifs, application de ces réactifs et kit diagnostic contenant ces réactifs | |
EP0528708B1 (fr) | Procédé et dispositif magnétique d'analyse immunologique sur phase solide | |
CH631016A5 (fr) | Dispositif de separation et de reaction pour analyse immunologique. | |
FR2963108A1 (fr) | Procede magnetique d'immunodiagnostic et kit pour la mise en evidence de complexe anticorps/antigene de groupe/phenotype sanguin | |
EP1320739A1 (fr) | Dispositif d'acheminement de reactifs et procede d'utilisation | |
JPH0212061A (ja) | 改良されたゾル捕捉イムノアッセイキット及び方法 | |
EP1342089A2 (fr) | Barriere de separation temporaire, recipient la comprenant et procede de mise en oeuvre d'un test dans ce recipient | |
WO1989010564A1 (fr) | Dispositif et procede pour la determination qualitative et quantitative rapide de la presence d'un ligand reactif dans un fluide | |
CA2565114A1 (fr) | Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees | |
EP0311492A2 (fr) | Trousse et méthode de dosage immunométrique applicables à des cellules entières | |
EP0512896B1 (fr) | Complexe agglutinant comme réactif de groupage sanguin | |
WO2002046773A1 (fr) | Dispositif et procede d'analyse immunologique | |
EP0542655A1 (fr) | Dispositif permettant de réaliser en un seul temps la séparation et la mise en évidence des agglutinats érythrocytaires | |
EP0544578B1 (fr) | Trousse pour le dénombrement rapide des granulocytes et procédé utilisant ladite trousse | |
EP0594506B1 (fr) | Procédé d'immunodiagnostic en matrice d'affinité poreuse avec particules sensibilisées et dispositif pour sa mise en oeuvre | |
EP0008245A1 (fr) | Système physico-biochimique pour la détection, le dosage et l'isolement de substances à activité antigénique | |
FR2538907A1 (fr) | Reactif immunologique constitue par des antigenes ou des anticorps en forme de cellules des particules ou des molecules ancres sur des surfaces solides continues par des unions ioniques ou covalents | |
WO2002016942A1 (fr) | Procede d'analyse immunologique par reaction d'adherence | |
JP2004170127A (ja) | 抗体試験のための血球試薬 | |
FR2790093A1 (fr) | Procede d'analyse immunologique par reaction d'adherence | |
EP0598014B1 (fr) | Utilisation d'atélocollagène comme support solide de fixation d'un capteur spécifique | |
FR2709349A1 (fr) | Procédé d'identification d'une substance immunologique au moyen d'un système multimembranaire. | |
FR2685956A1 (fr) | Procede et dispositif de test par agglutination de particules. | |
FR2549852A1 (fr) | Procede de realisation et de la suite des reactions enzymatiques et l'appareillage pour la mise en oeuvre du procede |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001999433 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001999433 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10433886 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001999433 Country of ref document: EP |